^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Abecma (idecabtagene vicleucel)

    i
    Company:
    2seventy bio, BMS
    Drug class:
    BCMA-targeted CAR-T immunotherapy
    Related drugs:
    Apply
    A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant (NCT05393804)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    05/20/2022
    Primary completion :
    05/01/2025
    Completion :
    05/01/2025
    SDC1
    |
    Abecma (idecabtagene vicleucel)
    MT2017-45: CAR-T Cell Therapy for Heme Malignancies (NCT03642626)
    Phase N/A
    Masonic Cancer Center, University of Minnesota
    Active, not recruiting
    Last update posted :
    03/18/2024
    Initiation :
    12/18/2018
    Primary completion :
    02/09/2024
    Completion :
    06/01/2028
    CD19
    |
    CD19 expression
    |
    cyclophosphamide • Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T) • fludarabine IV • Tecartus (brexucabtagene autoleucel) • Abecma (idecabtagene vicleucel) • cyclophosphamide intravenous
    MM CAR-T to Upgrade Response BMTCTN1902 (NCT05032820)
    Phase 2
    Marcelo Pasquini, MD
    Active, not recruiting
    Last update posted :
    01/08/2024
    Initiation :
    01/05/2022
    Primary completion :
    01/01/2025
    Completion :
    04/01/2025
    CD34
    |
    lenalidomide • cyclophosphamide • fludarabine IV • Abecma (idecabtagene vicleucel)